Vertex Grapples With Bearish Chart As Death Cross Emerges
Vertex Grapples With Bearish Chart As Death Cross Emerges
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) is grappling with bearish technical signals as its stock forms a dreaded Death Cross.
福泰製藥公司（納斯達克：VRTX）面臨看淡的技術信號，因爲其股票形成了可怕的死亡交叉。
Chart created using Benzinga Pro
圖表使用Benzinga Pro創建
This occurs when the 50-day moving average falls below the 200-day moving average, often seen as a harbinger of prolonged bearish momentum. For Vertex, the technical woes align with a broader decline—down 15% over six months and nearly 14% in the past month alone.
當50日移動平均線跌破200日移動平均線時，就會發生這種情況，通常被視爲長期看淡動能的先兆。對於福泰製藥而言，技術問題與更廣泛的下滑趨勢一致——過去六個月下跌了15%，而在過去一個月中則跌近14%。
Read Also: If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today
相關閱讀：如果你在20年前投資了1000美元在這隻股票上，今天你將擁有這麼多。
Cystic Fibrosis Successes Overshadowed By Painkiller Setback
囊性纖維化的成功被止痛藥的挫折所掩蓋。
Despite commanding over 90% of its revenue from its cystic fibrosis drug franchise, Vertex has been unable to fend off investor skepticism.
儘管其囊性纖維化藥物業務的營業收入佔比超過90%，福泰製藥仍未能抵擋住投資者的懷疑。
In 2024, the company made waves with CASGEVY, the first gene-editing-based treatment for Sickle Cell Disease. However, enthusiasm waned in December after its much-anticipated non-addictive painkiller failed to meet clinical trial goals, leading to an 11% slide in shares, according to Insider Monkey.
在2024年，該公司因CASGEVY引起關注，這是首個基於基因編輯的鐮刀型細胞疾病治療藥物。然而，在其備受期待的非上癮止痛藥未能達到臨牀試驗目標後，熱情在12月減退，導致股價下滑11%，根據Insider Monkey的報告。
VRTX Stock Charts Are Not Encouraging
福泰製藥的股票圖表並不樂觀
VRTX stock is flashing multiple sell signals:
福泰製藥股票發出多個賣出信號：
- Moving Averages: VRTX stock, at $402.49, is below all key averages, including the 50-day ($456.92) and 200-day ($457.35), reinforcing the Death Cross.
- MACD: A negative reading of -17.17 signals strong bearish momentum.
- RSI: At 32.59, the stock is approaching oversold levels but hasn't yet hit the reversal zone.
- 移動平均線：福泰製藥的股票當前價爲$402.49，低於所有關鍵平均線，包括50日移動平均線（$456.92）和200日移動平均線（$457.35），進一步鞏固死亡交叉。
- MACD：-17.17的負值顯示出強烈的看淡動能。
- 相對強弱指數（RSI）：當前值爲32.59，該股票接近超賣水平，但尚未觸及反轉區域。
Cramer's Call Under Pressure
克拉默的看漲呼籲面臨壓力
Back in August, Jim Cramer lauded Vertex as a promising player in biotech, emphasizing its groundbreaking work in cystic fibrosis and pain management.
在八月份，吉姆·克拉默讚揚福泰製藥是生物科技領域的有前途的參與者，強調其在囊性纖維化和疼痛管理方面的開創性工作。
Since then, the stock has dropped nearly 18%, reflecting the volatility that often plagues the biotech sector.
自那時以來，這隻股票已下跌近18%，反映出生物科技板塊常常遭遇的波動性。
Vertex's technical and fundamental challenges suggest that investors may need patience to see a rebound.
福泰製藥的技術和基本面挑戰表明，投資者可能需要耐心才能看到反彈。
- Vertex Pharmaceuticals: Alyftrek Is An 'Accretive Opportunity' On Top- And Bottom-Lines, Says Bullish Analyst
- 福泰製藥：分析師看好Alyftrek爲公司在收入和利潤方面提供了'增值機會'
Photo: Shutterstock
Photo: Shutterstock
譯文內容由第三人軟體翻譯。